Treatment response and drug resistance in patients infected with HIV type 1 group O viruses

AIDS Research and Human Retroviruses

Volumn 21, Issue 7, 2005, Pages 602-607

  Rodes, Berta ^a   De Mendoza, Carmen ^a   Rodgers, Mette ^b   Newell, Anthony ^b   Jimenez, Victoria ^a   Lopez Brugada, Rosa Maria ^a   Soriano, Vincent ^a,c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; DNA; INDINAVIR; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP O; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TYPING;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DNA PRIMERS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 23444438655     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.602     Document Type: Article

References (17)

1. Garcia Lerma J, Gutierrez M, Mas A, Bravo R, Aguilera O, and Soriano V: Report of the first two cases of HIV-1 group O infection in Spain. Med Clin (Barc) 1996;107:418-421.
2. Couturier E, Damond F, Roques P, Fleury H, Barin F, Brunet J, et al.: HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network. AIDS 2000;14:289-296.
3. Jonassen T, Stene-Johansen K, Berg E, Hungnes O, Lindboe C, Froland S, et al.: Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s. Virology 1997;231:43-47.
4. Britvan L, Gould K, Dryjanski J, Kerndt P, Mascola L, Sun R, et al.: Identification of HIV-1 group O infection-Los Angeles county, California, 1996. MMWR Morb Mortal Wkly Rep 1996;45:561-565.
5. Parkin N and Schapiro J: Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antiviral Ther 2004;9:3-12.
6. Nkengasong J, Adje-Toure C, and Weidle P: HIV antiretroviral drug resistance in Africa. AIDS Rev 2004;6:4-12.
7. Quinones-Mateu M, Albright J, Mas A, Soriano V, and Arts E: Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of HIV type 1. J Virol 1998;72:9002-9015.
8. De Baar M, Janssens W, De Ronde A, Fransen K, Colebunders R, Kestens L, et al.: Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res Hum Retroviruses 2000;16:1385-1394.
9. de Mendoza C, Lu W, Machuca A, Sainz M, Castilla J, and Soriano V: Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. J Med Virol 2001;64:217-222.
10. Rodes B, Poveda E, and Soriano V: Rapid assessment of phenotypic resistance to protease inhibitors in HIV type 1 group O. J Clin Microbiol 2002;40:4313-4316.
11. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004;12:119-124.
12. Yamaguchi J, Vallari A, Swanson P, et al.: Evaluation of HIV type 1 group O isolates: Identification of five phylogenetic clusters. AIDS Res Hum Retroviruses 2002;18:269-282.
13. Descamps D, Collin G, Letourneur F, Apretrei C, Damond F, Loussert-Ajaka I, et al.: Susceptibility of HIV type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genetic analyses. J Virol 1997;71:8893-8898.
14. Clemente J, Hemrajani R, Blum L, Goodenow M, and Dunn B: Secondary mutations M36I and A71V in the HIV type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 2003;42:15029-15035.
15. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, et al.: Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001;312:795-805.
16. Clavel F and Hance A: HIV drug resistance. N Engl J Med 2004;350:1023-1035.
17. Harrigan PR, Wynhoven B, Montaner J, McKenna P, and Bacheler L: Mutations at reverse transcriptase codon 103: Phenotypic resistance to non-nucleoside reverse transcriptase inhibitor and clinical correlates. XII International HIV Drug Resistance Workshop. Abstract 110. Antiviral Ther 2003;8(Suppl.):120.